At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 238 enrolled
Drug / intervention
fluticasone furoate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.
In Brief
A Phase 3 clinical trial evaluating fluticasone furoate and albuterol/salbutamol for Asthma. Completed, enrolled 238 participants across 40 sites in 6 countries.
Detailed Summary
A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of two doses of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Chile, France, Mexico, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedSep 2011
Primary CompletionOct 2012
TodayJul 2026
First PostedSep 12, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.8 years ago
Interventions
fluticasone furoatedrug
Inhaled corticosteroid
albuterol/salbutamoldrug
Provided as rescue relief of asthma symptoms